GEN Exclusives

More »

GEN News Highlights

Back to Item »

Cyclogenix Inks License and Research Deals Wyeth and IMBcom to Further Peptide Research

Wyeth will use Cyclogenix' discovery platform, and Cyclogenix will leverage IMBcom's technology and expertise for its R&D activities.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Cancer Drug Approvals and Efficacy

Do you think regulatory agencies should be required to provide stronger evidence of the clinical effectiveness of cancer drugs, including a greater emphasis on patient survival time?

More »